1 Conditional Survival and Nomogram for Elderly

2 Non-Metastatic Colon Cancer Patients Following Colectomy

3 Yadong Gao^{1,6}, Huimin Wang²*, Yi Zhang³, Jing Zhao⁴, Sujuan Feng⁵*,

4 Jianwei Qiu^{1*}

- Department of Gastroenterology, Affiliated Hospital 2 of Nantong University,
 Nantong, China
- Department of Cardiology, Affiliated Hospital 2 of Nantong University, Nantong,
 China
- 9 3. Department of Neurosurgery, Affiliated Hospital 2 of Nantong University,10 Nantong, China
- 11 4. Department of Dermatology, Affiliated Nantong Hospital 3 of Nantong University
- Department of Nephrology, Affiliated Hospital 2 of Nantong University, Nantong,
 China
- 14 6. Nantong Clinical Medical College of Kangda College, Nanjing Medical15 University, Nantong, China

16 * Correspondence:

- 17 Dr Jianwei Qiu, Department of Gastroenterology, Affiliated Hospital 2 of Nantong
- 18 University, 666 Shengli Road, Chongchuan District, Nantong 226001, China. E-mail:
- 19 ntfhqjw@163.com
- 20 Dr Huimin Wang, Department of Cardiology, Affiliated Hospital 2 of Nantong
- 21 University, 666 Shengli Road, Chongchuan District, Nantong 226001, China. E-mail:
- 22 wanghuimin1112@yeah.net
- 23 Dr Sujuan Feng, Department of Nephrology, Affiliated Hospital 2 of Nantong
- University, 666 Shengli Road, Chongchuan District, Nantong 226001, China. E-mail:
 takeucifsi@163.com
- 25 takeucifsj@163.com
- 26 Keywords: Conditional Survival; Colon Cancer; Colectomy; Nomogram; SEER

27 Ethical approval

- 28 The information used in our study was obtained from the SEER database,
- 29 which is accessible to the public, thus eliminating the need for ethical
- 30 clearance.

31 Sources of funding

32 This work was supported by the Project of Chinese Medicine

33 NOTEA This preprint reports new research that has pot been certified hypeen review and should not be used a source times of the source of t

Nantong Science and Technology Bureau project (MS2022021), Nantong 34 University Clinical Basic Research Special General Project (2022JY003), 35 the Research project of Nantong Clinical Medical College of Kangda 36 Nanjing Medical University (KD2022KYCXTD006, College of 37 KD2022KYJJZD026), Open Fund for National Key Laboratory of Tumor 38 System Medicine (KF2203-93), and Nantong City Health Commission 39 Research Project (MSZ2022010, MS2023073). 40 Acknowledgments 41 The invaluable support of ChatGPT was instrumental in enhancing the 42 sentence structure revisions. 43 **Conflict of Interest declaration** 44 45 The authors declare that they have no affiliations with or involvement in any organization or entity with any financial interest in the subject matter 46 or materials discussed in this manuscript. 47 48 49 50 51 52 53

- 54
- 55

56 Abstract

57 Background: This study aimed to evaluate the conditional survival (CS) 58 of elderly patients with non-metastatic colon cancer who underwent 59 colectomy and build conditional nomograms that can accommodate 60 varying survival periods and estimate survival rates.

Methods: Data from 9302 patients between 2004 and 2017 were obtained from the Surveillance, Epidemiology, and End Results database. CS was used to assess overall survival and colon-specific survival rates in patients who survived beyond a certain time period. Cox regression was used to select factors for nomogram development, and performance was evaluated using area under the receiver operating characteristic curve (AUC), calibration plot, and decision curve analysis (DCA).

Results: The 5-year conditional overall survival rates initially increased 68 slightly but then decreased over time. The rates at different time points 69 70 after diagnosis (baseline and 1-5 years) were 62.5, 63.2, 62.8, 62.1, 61.6, and 59.8%. In contrast, 5-year conditional colon-specific survival rates 71 consistently improved over the same period. These rates were 78.1, 80.9, 72 84.2, 86.9, 89.3, and 90.9%, respectively. Nomograms were developed 73 74 for baseline measurements and for patients who survived 1, 3, and 5 years. The performance of these nomograms, assessed using AUC, calibration 75 curves, and DCA, indicated good predictive capabilities. 76

77 Conclusion: CS provides valuable information on the medium- and

long-term survival probabilities of elderly patients with non-metastatic
colon cancer who underwent colectomy. The developed conditional
nomograms allowed for the estimation of survival probabilities across
different timeframes, facilitating a comprehensive understanding of
prognosis and collaborative decision making.

83

84 **1. Introduction**

Colon cancer is the third most common and deadly form of cancer 85 worldwide, accounting for 10% of all cancer cases¹. It mainly affects the 86 elderly population, with most patients aged > 60 years and a significant 87 number aged $> 75^2$. As the global population ages, a significant increase 88 89 in the prevalence of colon cancer is expected among older individuals. In the United States alone, the elderly population (65 years and older) is 90 expected to increase by 20% by 2030, leading to a parallel surge in colon 91 cancer cases³. Additionally, the number of adults aged ≥ 85 years is 92 expected to triple to 19 million by 2060, further contributing to the rise in 93 colon cancer cases. While there is no standardized definition of "elderly" 94 in relation to colon cancer, it generally includes individuals aged 65-75 or 95 older⁴⁻⁶. 96

Surgery is the preferred treatment for stage I–III colon cancer. Advances
in medical standards have made radical surgery more feasible in elderly
patients. Studies have shown an increase in the rate of radical surgery

among colon cancer patients aged ≥ 75 years who were diagnosed with stage I or II⁷. Surgical resection has been found to improve the prognosis of elderly colon cancer⁸⁻⁹. Improved perioperative management and comprehensive geriatric assessments have contributed to better tolerance to surgical treatment and improved quality of life in the elderly¹⁰. These factors have led to prolonged survival of elderly patients undergoing surgery.

Conditional survival (CS) is a statistical measure that estimates the 107 likelihood of survival for a specific duration after diagnosis or treatment, 108 considering the patient's current survival time¹¹. This approach provides a 109 more personalized prognosis that evolves over time, making it more 110 111 relevant and meaningful to patients than the traditional survival analysis. It allows physicians to tailor checkup schedules and content based on a 112 patient's unique survival pattern, enabling personalized adjustments. 113 Previous studies on conditional survival in colorectal cancer have been 114 conducted¹²⁻¹⁴, but most have included a diverse age range, and few have 115 focused exclusively on the older population. A nomogram, which is a 116 predictive tool for prognosis, has emerged as valuable in assessing the 117 chances of survival in elderly colon cancer patients¹⁵. However, the 118 nomogram overlooks the crucial aspect of incorporating patient survival 119 duration. This study aimed to investigate conditional survival rates in 120 elderly non-metastatic colon cancer patients who underwent colectomy, 121

122 while developing nomograms to assess their prognosis.

123

124 **2. Materials and methods**

125 **Data collection**

This study used data from the November 2020 release of the Surveillance, 126 127 Epidemiology, and End Results (SEER) database obtained specifically from SEER*Stat Version 8.4.2. The study adhered to the guidelines of the 128 1964 Declaration of Helsinki and was conducted according to the 129 STROCSS criteria. As per our institute's Ethics Committee, this study did 130 not require approval from an institutional review board because it used 131 de-identified public database information. The study included a subset of 132 133 elderly colon cancer patients who underwent colectomy and met the following criteria: (1) aged 70-89 years, (2) pathologically diagnosed 134 with stage I-III colon cancer, (3) had undergone colectomy, and (4) had 135 colon cancer as the only primary cancer. Patients who received 136 neoadjuvant therapy were excluded from the analysis because of their 137 potential effects on downstaging and prognostic factors. Patients without 138 clinicopathological data or survival information were excluded from this 139 study. A diagram outlining the screening process is presented in 140 Supplementary Figure 1. 141

142 Statistical analyses

143 In this study, the time from diagnosis to death from any cause was

referred to as overall survival (OS), while the time from diagnosis to 144 death, specifically from colon cancer, was referred to as colon-specific 145 survival (CSS). A multivariate Cox regression model was constructed to 146 assess the correlation between clinicopathological characteristics and 147 survival outcomes. Survival curves were generated using the 148 Kaplan-Meier method, and survival disparities were assessed using the 149 log-rank test. CS represents the likelihood of survival for an additional 150 specified time period (y years) after survival for a certain duration (x 151 years). This measure was derived from Kaplan-Meier survival data and 152 153 was mathematically expressed as CS(x|y) = S(x+y)/S(x), where S(x)represents the OS or CSS rate at x years, as estimated the Kaplan-Meier 154 method¹⁶. This study employed COS (x) and CCSS (x) as alternatives to 155 S(x) to determine the number of survivors in year x. The standardized 156 differences (d) method was used to compute variations in CS across the 157 subgroups¹⁷. When |d| was less than 0.1, it indicated negligible difference 158 within each group; when it ranged from 0.1 to less than 0.3, it signified a 159 minor difference; when it falled between 0.3 and less than 0.5, it 160 suggested a moderate difference; and when |d| was 0.5 or greater, it 161 indicated a notable difference. 162

163 The study participants were randomly allocated to either the training or 164 validation cohort with a distribution ratio of 7:3. Univariate Cox 165 regression analysis was performed to identify potential variables for

inclusion in multivariate analysis, with a requirement for significance of 166 p<0.05. Subsequently, variables demonstrating prognostic significance in 167 168 multivariate Cox regression analysis were used to construct nomograms. To evaluate the discriminative ability of the nomogram, the area under the 169 receiver operating characteristic (ROC) curve (AUC) was calculated. The 170 calibration assessment was conducted using the Brier score and a 171 calibration plot, employing the bootstrapping approach with 1000 172 resampling bootstraps. After the nomogram was subjected to decision 173 curve analysis (DCA), its clinical efficacy was assessed. 174

R version 4.1.1 was employed for statistical analysis. Categorical
variables are presented as frequencies and percentages, and disparities
among various groups were examined using the chi-squared test.
Continuous variables were expressed as means with standard deviations
and compared using the t-test or rank-sum test based on data distribution.
Statistical significance was determined using a p-value less than 0.05.

181

182 **3. Results**

183 Clinicopathological characteristics

This study encompassed 9302 cases from 2004 to 2017 based on specific criteria. As shown in Table 1, the training set consisted of 6511 patients, whereas the validation set comprised 2791 patients. The patients had an average age of 78.6 years with a standard deviation of 5.42. The majority

of these patients were female (57.4%), white (81.0%), diagnosed after 188 2010 (55.2%), and had tumors located in the proximal colon (73.1%). 189 190 Grade II patients constituted the largest proportion (70.2%), followed by grade III (19.7%), grade I (6.64%), and grade IV (3.48%) patients. Colon 191 adenocarcinoma was the most common cancer type (89.7%). Tumors < 5192 cm accounted for 58.0% of the cases, and the majority of patients were 193 married (51.6%) and had negative or normal carcino-embryonic antigen 194 (CEA) test results (62.6%). Tumor stages were classified as T1 (7.99%), 195 196 T2 (16.7%), T3 (61.2%), and T4 (14.1%). Nodal stages were classified as N0 (63.4%), N1 (24.6%), and N2 (12.0%). A small proportion of the 197 patients received radiotherapy (0.8%) or chemotherapy (22.5%). The 198 199 training and validation cohorts exhibited no significant differences in any of the variables. 200

201 COS and CCSS

the conditional survival curves. 202 Figure 1 shows The analysis demonstrated a consistent pattern of improvement in the actuarial OS and 203 CSS of individuals as the duration of survival increased annually. 204 Meanwhile, as shown in Table 2 and Figure 1, the COS5 rates initially 205 saw a marginal uptick, followed by a subsequent decline. Specifically, the 206 rates at baseline, one year, two years, three years, four years, and five 207 years post-diagnosis were 62.5%, 63.2%, 62.8%, 62.1%, 61.6%, and 208 59.8%, respectively. However, the CCSS5 rates exhibited an upward 209

trajectory over the five-year period, with the initial and subsequent
conditional survival rates at baseline and years 1 through 5 being 78.1%,
80.9%, 84.2%, 86.9%, 89.3%, and 90.9%, respectively (Table 3).

Subsequently, detailed subgroup analysis was conducted to assess the 213 impact of various factors on the rates of COS5 and CCSS5. The 214 expression rates of COS5 and CCSS5 varied across these subgroups, 215 displaying distinct patterns over time. For COS5, there were persistent 216 negligible or minor differences in survival between some subgroups 217 218 $(|d|<0.1) \ge 2010$ vs. < 2010, Distal vs. Poximal, Grade II vs. Grade I, and T2 vs. T1; 0.1<|d|<0.3: Widowed vs. Married and Separated/Divorced vs. 219 Married). The differences in COS5 levels between some subgroups 220 221 gradually appeared over time ($|d| < 0.1 \rightarrow |d| > 0.1$: Others vs. White and Chemotherapy Yes vs. None/Unknown). The disparity in COS5 rates 222 among some subgroups slowly diminished over time ($|d| > 0.1 \rightarrow |d| < 0.1$, 223 $|d|>0.3 \rightarrow |d|<0.3$, or $|d|>0.5 \rightarrow |d|<0.5$; black vs. White, Others vs. 224 proximal, grade III vs. Grade I, Grade IV vs. Grade I, Single vs. Married, 225 Positive/Elevated vs. Negative/Normal, T3 vs. T1, T4 vs. T1, N1 vs. N0, 226 and N2 vs. N0). Over time, the variance in the COS5 rate fluctuated 227 irregularly across other subgroups. Correspondingly, for CCSS5, there 228 were persistent negligible differences in survival between some 229 subgroups (|d| < 0.1: others vs. white, ≥ 2010 vs. < 2010, mucinous 230 adenocarcinoma vs. adenocarcinoma, owed vs. Married and T2 vs. T1). 231

232	The variance in CCSS5 among the subgroups became increasingly
233	evident as time progressed ($ d \le 0.1 \rightarrow d \ge 0.1$: Distal vs. Poximal). Over
234	time, there was a gradual reduction in the differences in CCSS5 rates
235	within certain subgroups ($ d \ge 0.1 \rightarrow d \le 0.1$, $ d \ge 0.3 \rightarrow d \le 0.3$, or $ d \ge 0.5 \rightarrow$
236	d <0.5: black vs. White, Grade II vs. Grade I, Grade IV vs. Grade I, ≥5
237	cm vs. < 5 cm, single vs. Married, Positive/Elevated vs. Negative/Normal,
238	T3 vs. T1, T4 vs. T1, N1 vs. N0, and N2 vs. N0). The differences in the
239	CCSS5 rate among the other subgroups fluctuated irregularly over time.

Variables linked to the OS and CSS in patients who have attained a defined duration of survival

Age, race, sex, year of diagnosis, site, grade, marital status, CEA level, T 242 243 stage, N stage, and chemotherapy were independent prognostic factors for OS at baseline (Table 4 and Supplementary Table 1). The prognostic 244 factors for patients who survived for at least one year differed from those 245 at baseline, including age, race, sex, marital status, CEA levels, T stage, N 246 stage, and chemotherapy. After three years, age, race, sex, histology type, 247 marital status, CEA levels, T stage, N stage, and chemotherapy 248 independently affected OS. At the 5-year mark, age, race, sex, marital 249 status, CEA levels, T stage, and chemotherapy were key predictors of OS, 250 consistent with the baseline and other survival intervals. 251

Age, year of diagnosis, site, grade, marital status, CEA, T stage, N stage,and chemotherapy were determined to be independent prognostic factors

for cancer-specific survival (CSS) at baseline, as indicated in Table 5 and 254 Supplementary Table 2. After a minimum of one year of survival, age, 255 256 CEA levels, T stage, N stage, and chemotherapy remained significant risk factors for CSS. For patients who survived beyond three years, age, sex, 257 tumor location, marital status, CEA levels, T stage, and N stage emerged 258 as influential factors. Among those who surpassed a five-year milestone, 259 age, tumor site, CEA level, and T stage were independent prognostic 260 factors. Constant predictors of CSS for newly diagnosed patients and 1-, 261 262 3-, and 5-year survivors were age, CEA, and T stage.

263 Conditional nomogram construction and validation

Figure 2 and 3 illustrate the OS and CSS nomograms developed for 264 265 cancer patients at different stages of their journey, including the start and at the one-year, three-year, and five-year milestones. These nomograms 266 consider the specific risk factors for each individual. Our investigation 267 delved deeper into the performances of these nomograms. Baseline 268 analysis of the OS nomogram in the training set revealed an area under 269 the curve (AUC) of 0.703, 0.713, and 0.713 for the one-year, three-year, 270 and five-year intervals, respectively (Figure 4). In the test set, the 271 corresponding AUC were 0.714, 0.722, and 0.719, respectively 272 (Supplementary Figure 2). For patients who survived for at least one year, 273 274 the OS nomogram showed AUC of 0.700, 0.697, and 0.698 in the training set and 0.698, 0.694, and 0.701 in the test set, respectively, for the same 275

intervals. For patients surviving for 3 years, the OS nomogram achieved 276 AUC of 0.652, 0.665, and 0.694 in the training set and 0.663, 0.666, and 277 278 0.688 in the test set, respectively. Additionally, for patients surviving 5 years, the training set's OS nomogram yielded AUC of 0.661, 0.694, and 279 0.695 for the one-year, three-year, and five-year durations. In the test set, 280 AUC were 0.590, 0.674, and 0.681 for the same intervals. Regarding the 281 CSS nomogram, at baseline, the training cohort demonstrated AUC 282 values of 0.771, 0.788, and 0.782 for the one-year, three-year, as well as 283 284 five-year periods (Figure 5), while the test cohort achieved corresponding AUC values of 0.787, 0.804, and 0.800, respectively (Supplementary 285 Figure 3). For patients who survived for 1 year, the training cohort CSS 286 287 nomogram attained AUC of 0.785, 0.795, and 0.781 for the one-year, three-year, and five-year intervals, whereas the test cohort displayed AUC 288 of 0.780, 0.778, and 0.761, respectively. Among patients surviving 3 289 years, the training cohort showed AUC of 0.765, 0.732, and 0.727 over 290 the one-year, three-year, and five-year periods, whereas the test cohort 291 displayed AUC of 0.786, 0.732, and 0.697, respectively, for the same 292 duration. For patients who survived for 5 years, the training cohort CSS 293 nomogram achieved AUC values of 0.664, 0.669, and 0.682 for the 294 one-year, three-year, and five-year periods, whereas the test cohort 295 296 showed AUC values of 0.585, 0.629, and 0.655, respectively.

297 The calibration curves of the OS and CCS nomograms when utilized for

these training and validation sets are also presented. The outcomes demonstrated strong concordance between anticipated and observed survival rates in both the training and validation sets, indicating the accuracy of these nomograms in predicting survival probabilities (Supplementary Figure 4-7). In addition, the DCA curves also indicated the favorable clinical utility of these nomograms (Supplementary Figure 8-11).

305

306 **4. Discussion**

In this investigation, we examined the survival data of elderly patients 307 with non-metastatic colon cancer who had undergone colectomy in detail. 308 309 The uniqueness and notable attributes of our research encompass the following: we conducted an analysis of the CS rates, allowing for a more 310 precise assessment of OS and CSS outcomes in both medium-term and 311 long-term survivors; this analysis aids in accurately forecasting survival 312 rates and advancing personalized medical approaches; our findings 313 revealed the nomograms to possess favorable discriminatory and 314 predictive capabilities when forecasting OS and CSS rates. 315

In the coming years, we expect a higher incidence of colon cancer in the elderly population. This can be attributed to a longer life expectancy and improved rates of survival¹⁸. Colectomy is the primary curative treatment for the elderly. Previous studies have reported a notable correlation

between surgical resection and improved prognosis in older patients with 320 colon cancer^{8-9,19}. However, the prognosis of elderly patients differs from 321 that of younger individuals owing to the presence of other health 322 conditions, functional disabilities, more advanced tumors, and a 323 decreased ability to maintain internal balance. Elderly patients experience 324 higher rates of complications and mortality following surgery as well as a 325 less favorable overall outlook^{3,20}. Given the complexities surrounding 326 older adults with colon cancer, there is an urgent need for further research 327 focusing on this demographic, particularly on those who have undergone 328 surgical procedures. Currently, there is limited information on the 329 medium- and long-term postoperative prognoses of elderly patients with 330 331 colon cancer, and few studies have investigated the practical application of prediction models specifically tailored to this population. Wang²¹ et al. 332 developed a prognostic model that accurately predicted the outcomes of 333 elderly patients with colorectal cancer. However, their study included 334 patients with and without metastatic disease, and it is widely recognized 335 differs significantly between that prognosis these two groups. 336 Additionally, their study focused only on CSS and not OS. To our 337 knowledge, this study is the first to investigate the development and 338 validation of a reliable nomogram for predicting both OS and CSS in 339 elderly adults with non-metastatic colon cancer who have undergone 340 colectomy. This model is expected to provide patients and healthcare 341

providers with a valuable tool for guiding follow-up care and treatmentdecisions.

CS provides a precise estimation of the likelihood of a specific time point 344 in the course of a disease, closely tied to individual long-term survival 345 rates based on patients' time of survival¹¹. This allows for a more accurate 346 depiction of prognostic outcomes. To our knowledge, this study is the 347 first to show CS in elderly individuals with non-metastatic colon cancer 348 who have undergone colectomy. In this study, survival analysis revealed 349 350 an upward trend in actuarial OS and CSS among elderly patients as their 351 survival duration increased annually. However, COS and CCSS rates showed contrasting patterns. Initially, the COS5 rates experienced a slight 352 353 increase, followed by a subsequent decrease, whereas the CCSS5 rates demonstrated a consistent upward trend over the five-year duration. 354 Compared with the previously noted trend of annual increases in the 355 likelihood of COS rates for malignant tumors^{11,13}, particularly CRC, this 356 study revealed a distinctive pattern of change in COS rates. Our 357 hypothesis attributed this variance to disparity in the cohort composition. 358 This study differs from previous research by exclusively focusing on 359 older adults instead of encompassing individuals across all age groups. 360 Throughout the course of follow-up, the impact of non-colon 361 cancer-related death determinants accumulated at various stages of the 362 life course, leading to a growing risk of other conditions such as 363

cardiovascular and cerebrovascular diseases among elderly patients with 364 colon cancer. a recent study²², it was found that the majority of deaths in 365 patients aged > 80 years during the follow-up period were unrelated to 366 CRC. Non-CRC-related causes of death, such as respiratory failure, 367 particularly aspiration pneumonia, cardiovascular disease, and sepsis, 368 were the primary contributors to mortality. Another study suggested that 369 cerebrovascular-specific hazard ratios were 3.10-, 6.67, and 10.95 times 370 greater for CRC patients aged 50-64, 65-74, and over 75 years, 371 respectively, compared to those under 50 years old²³. One of the foremost 372 concerns for those who survive cancer is the risk of mortality. Although 373 the risk of death due to colon cancer surpasses that of other illnesses in 374 375 the initial years, this specific risk diminishes over time in a discernible trend. Our research showed that over the span of five years, the CCSS5 376 showed a consistent increase, with the baseline and subsequent 377 conditional survival rates at years 1 through 5 documented as 78.1%, 378 80.9%, 84.2%, 86.9%, 89.3%, and 90.9%, respectively, indicating a 379 positive trend. The findings from the CS analysis could instill greater 380 optimism in the patients. For instance, consider a patient who initially has 381 a 5-year CSS of 78.1% at the time of diagnosis. Subsequently, through 382 dedicated adherence to treatment and follow-up, the patient successfully 383 achieved 5-year survival, and the CS analysis conveyed the encouraging 384 news: "Your 5-year CSS rate has risen to 90.9%." On the other hand, in 385

medRxiv preprint doi: https://doi.org/10.1101/2024.04.09.24305543; this version posted April 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

contrast to the general population's COS outcomes, the comparatively 386 less positive COS outcomes in the elderly indicate a greater need for 387 388 physicians to prioritize non-colonic causes of death as patients age. Subgroup analysis was performed to further understand the influence of 389 different variables on CS. The rates of COS5 and CCSS5 expression 390 varied in these subgroups. Over time, the variation in the rates of both 391 COS5 and CCSS5 among many subgroups gradually decreased (black vs. 392 White, Grade IV vs. Grade I, Single vs. Married, Positive/Elevated vs. 393 394 Negative/Normal, T3 vs. T1, T4 vs. T1, N1 vs. N0, and N2 vs. N0). One possible explanation is that patients in each subgroup with some high-risk 395 factors died over time, whereas the remaining patients had a better 396 397 prognosis, resulting in a smaller difference in survival between the subgroups. The change patterns of COS5 and CCSS5 differed among the 398 subgroups, which may be influenced by multiple factors, such as those 399 affecting cardiovascular death. Future studies of CS in these subgroups 400 should be conducted. 401

402 Our study examined the impact of various baseline prognostic factors on 403 patients with different survival durations. Multiple factors, including age, 404 race, sex, year of diagnosis, site, grade, marital status, carcinoembryonic 405 antigen (CEA) levels, T stage, N stage, and chemotherapy, significantly 406 influenced OS according to multifactor analysis. Upon reaching the 407 critical 5-year survival milestone, we identified several key independent

medRxiv preprint doi: https://doi.org/10.1101/2024.04.09.24305543; this version posted April 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

prognostic factors that consistently influenced the patient outcomes. 408 These factors included age, race, sex, marital status, CEA levels, T stage, 409 and chemotherapy, demonstrating a predictive value for OS across 410 baseline and 1-year, 3-year, and 5-year intervals. Furthermore, we 411 observed that at the beginning of the study, age, year of diagnosis, site, 412 grade, marital status, CEA levels, T stage, N stage, and chemotherapy 413 independently influenced CSS. However, as time progressed, only age, 414 CEA level, and T stage consistently emerged as predictive factors for CSS 415 416 in both newly diagnosed patients and those who survived for 1, 3, and 5 years. These variables, as observed in previous studies, could predict OS 417 and CSS at the beginning of diagnosis^{15,19,21}, but their predictive 418 419 significance diminished over time. To provide more accurate prognostic predictions, we utilized these variables to create nomograms for each type 420 of survival, which demonstrated good prediction performance and a 421 correspondingly good match between the predicted and observed survival 422 rates in the calibration plots. The practical application of these 423 nomograms is also supported by their favorable clinical utility, as shown 424 in the DCA curves. However, it should be noted that, as time progressed, 425 the AUC values of the nomograms gradually declined, indicating a 426 decrease in predictive accuracy. This trend can be explained by the 427 diminishing impact of clinicopathological factors on the prognosis over 428 time. Further research is needed to assess the latest clinical and laboratory 429

factors at specific time points to more accurately identify prognostic 430 factors affecting elderly colon cancer survivors. This study had some 431 432 limitations. First, given the retrospective nature of the study, it inevitably introduced a degree of selection bias owing to its inherent design. Second, 433 obtaining postoperative complications and adjuvant treatment details 434 from the SEER database for all patients is not feasible, potentially 435 impacting the survival prognosis of elderly individuals with colon cancer. 436 Third, the analysis of CS necessitates extensive data, thus posing 437 438 challenges for the external validation of these nomograms. Furthermore, the ongoing update of nomograms is essential to accommodate the 439 evolving treatment strategies. 440

441

442 **5. Conclusion**

We reported the rates of CS in elderly non-metastatic colon cancer patients following colectomy, enhancing our understanding of survival rates in the medium- and long-term. We also created personalized CS nomograms to predict mortality risk at different intervals. These tools aid surgeons and patients in making informed decisions, and contribute to personalized medicine.

449

450

451

452

- 453 **Table 1.** Baseline characteristics of enrolled patients
- **Table 2.** Five-year conditional overall survival rates (%).
- **Table 3.** Five-year conditional colon-specific survival rates (%).
- **Table 4.** Multivariate analyses of overall deaths in baseline, \geq one-, three-,

457 five-year survivors in the training cohort.

Table 5. Multivariate analyses of colon-specific deaths in baseline, \geq one-,

459 three-, five-year survivors in the training cohort.

460

Figure 1. Conditional survival analysis of elderly non-metastatic colon cancer patients who undergo colectomy. (A) Kaplan–Meier curves estimating overall survival for individuals who had successfully survived a duration of 0-6 years. (B) Kaplan–Meier curves estimating colon-specific survival for individuals who had successfully survived a duration of 0-6 years.

467 Figure 2. Nomograms to predict one-, three-, and five- overall survival
468 for baseline (A), one-year (B), three-year (C), and five-year (D)
469 survivors.

Figure 3. Nomograms to predict one-, three-, and five-year colon-specific
survival for baseline (A), one-year (B), three-year (C), and five-year (D)
survivors.

473 Figure 4. ROC curve analyses in the training cohort for one-, three-, and

five-year overall survival in baseline (A), one-year (B), three-year (C),
and five-year (D) survivors. ROC, receiver operator characteristic curve;
AUC, area under the curve.
Figure 5. ROC curve analyses in the training cohort for one-, three-, and
five-year colon-specific survival in baseline (A), one-year (B), three-year
(C), and five-year (D) survivors. ROC, receiver operator characteristic
curve; AUC, area under the curve.

482 **Supplementary Table 1.** Univariate analyses of overall deaths in 483 baseline, \geq one-, three- and five-year survivors in the training cohort.

484 **Supplementary Table 2.** Univariate analysis of colon-specific deaths at 485 baseline, \geq one-, three- and five-year survivors in the training cohort.

486 Supplementary Figure 1. Flow diagram for enrollment of the study487 cohort.

Supplementary Figure 2. ROC curve analyses in the test cohort for one-,
three-, and five-year overall survival in baseline (A), one-year (B),
three-year (C), and five-year (D) survivors. ROC, receiver operator
characteristic curve; AUC, area under the curve.

492 Supplementary Figure 3. ROC curve analyses in the test cohort for one-,
493 three-, and five-year colon-specific survival in baseline (A), one-year (B),
494 three-year (C), and five-year (D) survivors. ROC, receiver operator
495 characteristic curve; AUC, area under the curve.

Supplementary Figure 4. Calibration curves of baseline nomograms. (A,
C and E) showed Calibration curves of nomograms in predicting one-,
three-, and five-year OS, respectively. (B, D and F) showed Calibration
curves of nomograms in predicting one-, three-, and five-year CSS,
respectively. OS, overall survival; CSS, colon-specific survival.

Supplementary Figure 5. Calibration curves of one-year survivors nomograms. (A, C and E) showed Calibration curves of nomograms in predicting one-, three-, and five-year OS, respectively. (B, D and F) showed Calibration curves of nomograms in predicting one-, three-, and five-year CSS, respectively. OS, overall survival; CSS, colon-specific survival.

Supplementary Figure 6. Calibration curves of three-year survivors nomograms in the training cohort. (A, C and E) showed Calibration curves of nomograms in predicting one-, three-, and five-year OS, respectively. (B, D and F) showed Calibration curves of nomograms to predict one-, three-, and five-year CSS, respectively. OS, overall survival; CSS, colon-specific survival.

513 **Supplementary Figure 7.** Calibration curves of five-year survivors 514 nomograms in the training cohort. (A, C and E) showed Calibration 515 curves of nomograms in predicting one-, three-, and five-year OS, 516 respectively. (B, D and F) showed Calibration curves of nomograms in 517 predicting one-, three-, and five-year CSS, respectively. OS, overall

518 survival; CSS, colon-specific survival.

Supplementary Figure 8. Decision curve analysis for overall survival
nomograms in the training cohort. A, patients at baseline; B, Patients who
have survived for one year; C, Patients who have survived for three years;
D, Patients who have survived for five years.

Supplementary Figure 9. Decision curve analysis for overall survival
nomograms in the test cohort. A, patients at baseline; B, patients who
have survived for one year; C, patients who have survived for three years;
D, patients who have survived for five years.

527 **Supplementary Figure 10**. Decision curve analysis for colon-specific 528 survival nomograms in the training cohort. A, patients at baseline; B, 529 patients who have survived for one year; C, patients who have survived 530 for three years; D, patients who have survived for five years.

Supplementary Figure 11. Decision curve analysis for colon-specific
survival nomograms in the test cohort. A, patients at baseline; B, patients
who have survived for one year; C, patients who have survived for three
years; D, patients who have survived for five years.

535

536 **Reference**

537 1. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and
538 survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363-385.

539 2. Papamichael D, Audisio RA, Glimelius B, et al. Treatment of

colorectal cancer in older patients: International Society of Geriatric
Oncology (SIOG) consensus recommendations 2013. Ann Oncol.
2015;26(3):463–476.

543 3. Ioffe D, Dotan E. Guidance for Treating the Older Adults with
544 Colorectal Cancer. Curr Treat Options Oncol. 2023;24(6):644-666.

4. Chen J, Zhang C, Wu Y. Does adjuvant chemotherapy improve
outcomes in elderly patients with colorectal cancer? A systematic review
and meta-analysis of real-world studies. Expert Rev Gastroenterol
Hepatol. 2022;16(4):383-391.

549 5. Choi DW, Kang H, Zhang HS, Jhang H, Jeong W, Park S. Association
550 of polypharmacy with all-cause mortality and adverse events among
551 elderly colorectal cancer survivors. Cancer. 2023;129(17):2705-2716.

552 6. Sanoff HK, Carpenter WR, Stürmer T, et al. Effect of adjuvant
553 chemotherapy on survival of patients with stage III colon cancer
554 diagnosed after age 75 years. J Clin Oncol. 2012;30(21):2624-2634.

555 7. Mitry E, Bouvier AM, Esteve J, et al. Improvement in colorectal
556 cancer survival: a population-based study. Eur J Cancer.
557 2005;41(15):2297-2303.

8. Bhangu A, Kiran RP, Audisio R, Tekkis P. Survival outcome of
operated and non-operated elderly patients with rectal cancer: A
Surveillance, Epidemiology, and End Results analysis. Eur J Surg Oncol.
2014;40(11):1510-1516.

- 562 9. Zhang L, Li Q, Hu C, Zhang Z, She J, Shi F. Real-world analysis of 563 survival benefit of surgery and adjuvant therapy in elderly patients with
- 564 colorectal cancer. Sci Rep. 2023;13(1):14866.
- 565 10. Ioffe D, Dotan E. Guidance for Treating the Older Adults with
- 566 Colorectal Cancer. Curr Treat Options Oncol. 2023;24(6):644-666.
- 567 11. Hagens ERC, Feenstra ML, Eshuis WJ, et al. Conditional survival
- ⁵⁶⁸ after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer.
- 569 Br J Surg. 2020;107(8):1053-1061.
- 570 12. Qaderi SM, Dickman PW, de Wilt JHW, et al. Conditional Survival
- and Cure of Patients With Colon or Rectal Cancer: A Population-Based
 Study. J Natl Compr Canc Netw. 2020;18(9):1230-1237.
- 13. Han L, Dai W, Mo S, et al. Nomogram of conditional survival
 probability of long-term Survival for Metastatic Colorectal Cancer: A
 Real-World Data Retrospective Cohort Study from SEER database. Int J
 Surg. 2021;92:106013.
- 577 14. Karagkounis G, Liska D, Kalady MF. Conditional Probability of
- 578 Survival After Neoadjuvant Chemoradiation and Proctectomy for Rectal
- 579 Cancer: What Matters and When. Dis Colon Rectum. 2019;62(1):33-39.
- 580 15. Yu C, Zhang Y. Establishment of prognostic nomogram for elderly
- colorectal cancer patients: a SEER database analysis. BMC Gastroenterol.
- 582 2020;20(1):347.
- 583 16. Kurta ML, Edwards RP, Moysich KB, et al. Prognosis and conditional

disease-free survival among patients with ovarian cancer. J Clin Oncol.
2014;32(36):4102-4112.

- 586 17. Cucchetti A, Piscaglia F, Cescon M, et al. Conditional survival after
- 587 hepatic resection for hepatocellular carcinoma in cirrhotic patients. Clin
- 588 Cancer Res. 2012;18(16):4397-4405.
- 589 18. Quaglia A, Tavilla A, Shack L, et al. The cancer survival gap between
- 590 elderly and middle-aged patients in Europe is widening. Eur J Cancer.
- 591 2009;45(6):1006–1016.
- 592 19. Zheng P, Lai C, Yang W, et al. Nomogram predicting cancer-specific
- survival in elderly patients with stages I-III colon cancer. Scand JGastroenterol. 2020;55(2):202-208.
- 595 20. Bouvier AM, Launoy G, Lepage C et al. Trends in the management
- and survival of digestive tract cancers among patients aged over 80 years.
- 597 Aliment Pharmacol Ther. 2005;22(3):233-241.
- 598 21. Wang Z, Wang Y, Yang Y, et al. A competing-risk nomogram to
 599 predict cause-specific death in elderly patients with colorectal cancer
 600 after surgery (especially for colon cancer). World J Surg Oncol.
 601 2020;18(1):30.
- 602 22. Ogata T, Yoshida N, Sadakari Y, et al. Colorectal cancer surgery in
 603 elderly patients 80 years and older: a comparison with younger age
 604 groups. J Gastrointest Oncol. 2022;13(1):137-148.
- 605 23. Dai ZH, Tang M, Chen YL, et al. Incidence and Risk Factors for

- 606 Cerebrovascular-Specific Mortality in Patients with Colorectal Cancer: A
- 607 Registry-Based Cohort Study Involving 563,298 Patients. Cancers
- 608 (Basel). 2022;14(9):2053. Published 2022 Apr 19.

609

Table 1 Baseline characteristics of enrolled patients

1

	Total (N=9302)	Train (N=6511)	Test (N=2791)	р
Age	78.6 (5.42)	78.6 (5.44)	78.6 (5.40)	0.894
Race				0.360
White	7533 (81.0%)	5293 (81.3%)	2240 (80.3%)	
Black	532 (5.72%)	359 (5.51%)	173 (6.20%)	
Others	1237 (13.3%)	859 (13.2%)	378 (13.5%)	
Sex:				0.744
Male	3964 (42.6%)	2767 (42.5%)	1197 (42.9%)	
Female	5338 (57.4%)	3744 (57.5%)	1594 (57.1%)	
Year of Diagnosis:				0.643
< 2010	4165 (44.8%)	2926 (44.9%)	1239 (44.4%)	
≥2010	5137 (55.2%)	3585 (55.1%)	1552 (55.6%)	
Site:				0.100
Poximal	6802 (73.1%)	4803 (73.8%)	1999 (71.6%)	
Distal	2383 (25.6%)	1629 (25.0%)	754 (27.0%)	
Others	117 (1.26%)	79 (1.21%)	38 (1.36%)	
Grade:				0.689
Grade I	618 (6.64%)	436 (6.70%)	182 (6.52%)	
Grade II	6532 (70.2%)	4549 (69.9%)	1983 (71.0%)	
Grade III	1828 (19.7%)	1299 (20.0%)	529 (19.0%)	
Grade IV	324 (3.48%)	227 (3.49%)	97 (3.48%)	
Histology Type:				0.199
Adenocarcinoma	8343 (89.7%)	5834 (89.6%)	2509 (89.9%)	
Mucinous adenocarcinoma	769 (8.27%)	533 (8.19%)	236 (8.46%)	
Others	190 (2.04%)	144 (2.21%)	46 (1.65%)	
Tumor Size:				0.961
< 5 cm	5394 (58.0%)	3774 (58.0%)	1620 (58.0%)	
≥5 cm	3908 (42.0%)	2737 (42.0%)	1171 (42.0%)	
Marital Status:				0.305
Married	4803 (51.6%)	3372 (51.8%)	1431 (51.3%)	
Single	831 (8.93%)	566 (8.69%)	265 (9.49%)	
Widowed	2892 (31.1%)	2045 (31.4%)	847 (30.3%)	
Separated/Divorced	776 (8.34%)	528 (8.11%)	248 (8.89%)	
CEA:				0.535
Negative/Normal	5825 (62.6%)	4091 (62.8%)	1734 (62.1%)	
Positive/elevated	3477 (37.4%)	2420 (37.2%)	1057 (37.9%)	
T stage:				0.282
T1	743 (7.99%)	513 (7.88%)	230 (8.24%)	
T2	1553 (16.7%)	1086 (16.7%)	467 (16.7%)	
T3	5697 (61.2%)	4022 (61.8%)	1675 (60.0%)	
T4	1309 (14.1%)	890 (13.7%)	419 (15.0%)	
N stage:				0.576
N0	5899 (63.4%)	4141 (63.6%)	1758 (63.0%)	
N1	2290 (24.6%)	1606 (24.7%)	684 (24.5%)	
N2	1113 (12.0%)	764 (11.7%)	349 (12.5%)	

Radiation				0.177
None/Unknown	9228 (99.2%)	6465 (99.3%)	2763 (99.0%)	
Yes	74 (0.80%)	46 (0.71%)	28 (1.00%)	
Chemotherapy:				0.468
None/Unknown	7206 (77.5%)	5030 (77.3%)	2176 (78.0%)	
Yes	2096 (22.5%)	1481 (22.7%)	615 (22.0%)	

5

Table 2 Five-year conditional overall survival rates (%).

		At	At 1	At 2	At 3	At 4	At 5
Variables		baseline	year	years	years	years	years
Total		62.5	63.2	62.8	62.1	61.6	59.8
Race							
	White	62.4	63.0	62.2	61.4	60.6	58.8
	Black	56.9	58.1	59.5	56.7	58.0	57.2
	Others	65.6	66.4	67.4	68.1	68.8	66.7
	d (Black vs. White)	-0.114	-0.102	-0.056	-0.097	-0.053	-0.032
	d (Others vs. White)	0.066	0.071	0.108	0.138	0.167	0.161
Sex	Male	60.2	60.3	59.1	58.6	58.3	58.1
	Female	64.3	65.3	65.6	64.6	64.0	61.0
	d (Female vs. Male)	0.085	0.104	0.134	0.124	0.117	0.059
Year of	- 2010						
diagnosis	< 2010	61.2	62.3	62.3	62.6	61.9	60.0
	≥2010	63.5	63.9	63.3	61.3	61.1	60.3
	d(2010) = 2010						
	$d (\geq 2010 \text{ vs.} \leq 2010)$	0.048	0.033	0.021	-0.028	-0.016	0.006
Site	Poximal	62.6	63.4	63.5	62.5	62.3	60.1
	Distal	63.2	63.3	61.5	61.3	60.0	59.1
	Others	0.414	47.8	49.0	48.7	55.2	59.0
	d (Distal vs. Poximal)	0.012	-0.002	-0.041	-0.025	-0.047	-0.020
	d (Others vs. Poximal)	-0.438	-0.323	-0.300	-0.284	-0.146	-0.022
Grade	Grade I	67.4	66.5	66.2	63.9	62.7	61.1
	Grade II	64.3	63.8	62.8	62.3	62.0	60.4
	Grade III	56.0	60.0	62.0	61.0	60.4	57.5
	Grade IV	53.3	60.9	59.3	58.5	55.5	57.2
	d (Grade II vs. Grade I)	-0.064	-0.056	-0.070	-0.033	-0.014	-0.014
	d (Grade III vs. Grade I)	-0.235	-0.135	-0.087	-0.060	-0.047	-0.073
	d (Grade IV vs. Grade I)	-0.291	-0.116	-0.143	-0.111	-0.148	-0.080
Histology type	Adenocarcinoma	63.0	63.6	63.1	62.3	62.2	60.7
	Mucinous adenocarcinoma	58.9	58.7	59.4	57.8	54.5	51.5
	Others	54.9	61.3	63.5	70.5	70.6	54.0
	d (Mucinous adenocarcinoma vs.						
	Adenocarcinoma)	-0.085	-0.102	-0.077	-0.093	-0.158	-0.188
	d (Others vs. Adenocarcinoma)	-0.167	-0.048	0.008	0.169	0.173	-0.137
	< 5cm						
Tumor size		65.5	65	63.5	63.3	63.5	61.8
	≥5cm	58.4	60.5	61.7	60.2	58.7	56.7

	$d \ge 5 \text{ cm vs.} < 5 \text{ cm}$	-0.147	-0.093	-0.037	-0.064	-0.099	-0.104
Marital status	Married	65.7	66.9	66.1	65.8	65.3	63.6
	Single	59.3	60.3	62.6	63.9	64.4	63.8
	Widowed	58.7	58.3	58	55.9	55.0	53.0
	Separated/Divorced	60.2	61.0	59.9	59.4	59.4	56.8
	d (Single vs. Married)	-0.132	-0.137	-0.072	-0.039	-0.019	0.004
	d (Widowed vs. Married)	-0.145	-0.178	-0.168	-0.204	-0.212	-0.216
	d (Separated/Divorced vs.						
	Married)	-0.114	-0.122	-0.128	-0.132	-0.121	-0.139
CEA	Negative/Normal	68.4	67.8	66.5	64.8	64.2	62.4
	Positive/Elevated	52.6	54.8	55.7	56.6	55.9	53.9
	d (Positive/Elevated vs.						
	Negative/Normal)	-0.326	-0.270	-0.223	-0.169	-0.171	-0.173
T stage	T1	77.8	76.6	73.9	69.4	67.8	65.0
	T2	75.0	73.6	69.6	66.2	64.1	61.5
	T3	62.1	61.8	61.4	61.3	60.9	59.4
	T4	40.6	46.1	50.0	51.8	54.0	53.1
	d (T2 vs. T1)	-0.058	-0.062	-0.089	-0.066	-0.076	-0.071
	d (T3 vs. T1)	-0.324	-0.307	-0.259	-0.167	-0.142	-0.114
	d (T4 vs. T1)	-0.768	-0.632	-0.494	-0.363	-0.284	-0.243
N stage	NO	70.0	69.0	66.4	64.1	62.8	60.1
	N1	54.9	56.4	58.1	58.9	58.9	58.3
	N2	38.3	42.6	48.3	53.9	58.5	61.2
	d (N1 vs. N0)	-0.312	-0.261	-0.172	0.107	-0.080	-0.037
	d (N2 vs. N0)	-0.655	-0.547	-0.374	-0.210	-0.088	0.022
Radiation	None/Unknown	62.6	63.2	62.8	62.1	61.7	59.9
	Yes	47.3	52.8	58.3	56.1	44.5	45.7
	d (Yes vs. None/Unknown)	-0.316	-0.216	-0.093	-0.124	-0.354	-0.290
Chemotherapy	None/Unknown	62.4	63.0	62.0	60.5	59.8	57.5
	Yes	62.9	63.7	65.6	67.4	67.7	67.9
	d (Yes vs. None/Unknown)	0.010	0.015	0.074	0.142	0.162	0.212

6 Table 3 Five-year conditional colon-specific survival rates (%).

		At	At 1	At 2	At 3	At 4	At 5
Variables		baseline	year	years	years	years	years
Total		78.1	80.9	84.2	86.9	89.3	90.9
Race							
	White	78.3	81.5	84.8	87.3	89.5	90.8
	Black	73.1	74.5	79.1	82.5	86.5	89.5
	Others	78.4	80.0	82.2	86.2	89.4	90.4
	d (Black vs. White)	-0.126	-0.178	-0.156	-0.142	-0.097	-0.045
	d (Others vs. White)	0.002	-0.038	-0.071	-0.033	-0.003	-0.014
Sex	Male	77.8	80.0	82.4	84.7	87.7	89.3
	Female	78.3	81.6	85.4	88.5	90.5	91.6
	d (Female vs. Male)	0.012	0.041	0.082	0.113	0.090	0.080
Year of	- 2010						
diagnosis	< 2010	77.1	80.1	83.8	87.0	89.3	90.9

	≥2010	78.9	81.7	84.4	86.7	89.2	89.6
	d (≥2010 vs. ≤ 2010)	0.044	0.041	0.016	0.000	0.002	0.045
<u></u>		0.044	0.041	0.016	-0.009	-0.003	-0.045
Site	Poximal	78.1	81.5	85.6	88.2	90.7	91.9
	Distal	78.3	79.7	80.6	83.7	86.0	87.5
	Others	68.1	74.9	77.6	82.7	85.5	91.2
	d (Distal vs. Poximal)	0.005	-0.046	-0.137	-0.133	-0.152	-0.153
	d (Others vs. Poximal)	-0.242	-0.168	-0.219	-0.163	-0.168	-0.024
Grade	Grade I	85.6	86.2	87.9	89.1	91.3	92.6
	Grade II	80.0	81.5	84.0	86.7	89.4	90.7
	Grade III	70.5	77.4	83.6	86.7	88.1	89.2
	Grade IV	67.2	77.2	82.4	87.7	89.7	94.3
	d (Grade II vs. Grade I)	-0.135	-0.120	-0.107	-0.071	-0.061	-0.066
	d (Grade III vs. Grade I)	-0.365	-0.224	-0.118	-0.071	-0.104	-0.118
	d (Grade IV vs. Grade I)	-0.445	-0.229	-0.151	-0.041	-0.052	0.059
Histology type	Adenocarcinoma	78.5	81.2	84.3	86.9	89.3	90.8
	Mucinous adenocarcinoma	76.3	78.7	83.5	86.9	89.3	88.6
	Others	64.6	76.0	82.1	91.3	92.3	NA
	d (Mucinous adenocarcinoma vs.						
	Adenocarcinoma)	-0.053	-0.064	-0.022	0	0	-0.076
	d (Others vs. Adenocarcinoma)	-0.336	-0.132	-0.060	0 130	0.097	NA
		0.000	0.132	0.000	0.120	0.077	1 11 1
Tumor size	< 5cm	813	82 7	84 8	87 5	89 7	90.8
Tullior Size	>5cm	73 5	02.7 78 3	83.1	86.0	88.8	90.0
	<u>_</u> 30m	15.5	70.5	05.1	00.0	00.0	JU. 1
	d (\geq 5cm vs. < 5cm)	0 180	0.112	0.047	0.044	0.020	0.014
Marital status	Marriad	-0.109	-0.112 82.0	-0.047	-0.044 87.0	-0.029	-0.014
Maritar status	Single	19.J 75.2	02.0 77.4	04.J 80.0	07.0 07.7	09.7	91.0
		75.5	77.4	80.9 94.1	04. <i>1</i>	00.3	90.2
		/0.8	/9.8	84.1	87.2	89.2	90.0
	Separated/Divorced	/6.9	82.2	85.6	87.5	8/./	86.7
	d (Single vs. Married)	-0.101	-0.11/	-0.099	-0.068	-0.045	-0.014
	d (Widowed vs. Married)	-0.065	-0.056	-0.011	0.006	-0.016	-0.028
	d (Separated/Divorced vs. Married)	-0.063	0.005	0.030	0.015	-0.065	-0.143
CEA	Negative/Normal	83.8	85.4	87.6	89.5	91.1	92.0
	Positive/Elevated	68.1	72.6	77.5	81.7	85.4	87.4
	d (Positive/Elevated vs.						
	Negative/Normal)	-0.380	-0.326	-0.277	-0.231	-0.184	-0.160
T stage	T1	94.2	95.0	94.7	94.4	94.4	94.4
	T2	92.7	93.4	93.5	93.6	93.9	93.8
	Τ3	78	79.9	83.1	85.9	88.3	89.8
	T4	50.8	58.2	65.7	72.7	80.5	84.8
	d (T2 vs. T1)	-0.036	-0.041	-0.033	-0.024	-0.016	-0.021
	d (T3 vs. T1)	-0.392	-0.384	-0.318	-0.252	-0.197	-0.160
	d (T4 vs. T1)	-1.049	-0.936	-0.795	-0.643	-0.450	-0.334
N stage	N0	88.1	89.2	90.2	91.0	92.1	92.4
2	N1	67.9	70.8	75.6	80.7	84.5	86.9
	N2	46.2	53.2	62.3	70.0	78.3	85.2
	d (N1 vs. N0)	-0.488	-0.468	-0.400	-0.305	-0.246	-0.191
	d (N2 vs. N0)	-1.013	-0.916	-0.765	-0.622	-0.446	-0.250

Radiation	None/Unknown	78.2	81.1	84.3	87.0	89.4	90.7
	Yes	57.1	61.1	70.6	78.4	80.1	NA
	d (Yes vs. None/Unknown)	-0.510	-0.509	-0.376	-0.255	-0.301	NA
Chemotherapy	None/Unknown	80.5	83.8	86.7	89.0	91.0	91.6
	Yes	70.2	71.8	75.9	80.2	83.9	87.5
	d (Yes vs. None/Unknown)	-0.249	-0.305	-0.296	-0.261	-0.230	-0.143

Table 4. Multivariate analyses of overall deaths in baseline, \geq one-, three-, five-year survivors in the training cohort.

Variables		Baseline survivors		> 1 year survivors		> 3 year survivors		> 5 year survivors	
		HR	р	HR	р	HR	р	HR	р
Age		1.07 (1.06-1.08)	< 0.001	1.08 (1.07-1.08)	< 0.001	1.09 (1.08-1.10)	< 0.001	1.10 (1.09-1.12)	< 0.001
Race	White	Ref		Ref		Ref			
	Black	1.20 (1.04-1.38)	0.010	1.10 (0.95-1.28)	0.217	1.06 (0.87-1.29)	0.579	1.14 (0.90-1.44)	0.287
	Others	1.20 (1.04-1.38)	< 0.001	0.77 (0.69-0.85)	< 0.001	0.77 (0.67-0.87)	< 0.001	0.69 (0.62-0.77)	< 0.001
Sex	Male	Ref		Ref		Ref			
	Female	0.73 (0.68-0.78)	< 0.001	0.71 (0.66-0.77)	< 0.001	0.67 (0.61-0.74)	< 0.001	0.69 (0.62-0.77)	< 0.001
Year of diagnosis	< 2010								
C	≥2010	0.90 (0.84-0.98)	0.004						
Site	Poximal	Ref							
	Distal	1.04 (0.97-1.12)	0.346						
	Others	1.52 (1.16-2.00)	0.003						
Grade	Grade I	Ref		Ref					
	Grade II	1.04 (0.91-1.19)	0.537	0.96 (0.83-1.10)	0.524				
	Grade III	1.17 (1.01-1.35)	0.035	0.97 (0.83-1.13)	0.672				
	Grade IV	1.21 (0.98-1.50)	0.074	0.97 (0.76-1.24)	0.672				
Histology type	Adenocarcinoma	Ref		Ref		Ref		Ref	
	Mucinous adenocarcinoma	1.04 (0.93-1.16)	0.462	1.04 (0.92-1.18)	0.494	1.06 (0.92-1.23)	0.393	1.09 (0.92-1.30)	0.311
	Others	0.81 (0.64-1.01)	0.064	0.90 (0.68-1.18)	0.452	0.65 (0.45-0.95)	0.025	0.80 (0.52-1.22)	0.297
Tumor size	< 5cm	Ref		Ref				Ref	
	≥5cm	1.01 (0.94-1.08)	0.794	0.96 (0.89-1.04)	0.324			1.03 (0.92-1.14)	0.608
Marital status	Married	Ref		Ref		Ref		Ref	
	Single	1.09 (0.97-1.23)	0.152	1.12 (0.98-1.28)	0.089	1.21 (1.03-1.41)	0.02	1.02 (0.83-1.24)	0.874
	Widowed	1.14 (1.05-1.23)	0.001	1.15 (1.05-1.25)	0.002	1.24 (1.12-1.37)	< 0.001	1.22 (1.08-1.38)	0.002
	Separated/Divorced	1.45 (1.29-1.64)	< 0.001	1.36 (1.19-1.56)	< 0.001	1.47 (1.25-1.73)	< 0.001	1.57 (1.29-1.92)	< 0.001
CEA	Negative/Normal	Ref				Ref			
	Positive/Elevated	1.38 (1.29-1.47)	< 0.001	1.35 (1.25-1.45)	< 0.001	1.39 (1.26-1.50)	< 0.001	1.26 (1.13-1.40)	< 0.001

11

T stage T	1	Ref	Ref		Ref		Ref	
Tž	2	1.03 (0.88-1.20) 0.74	6 0.99 (0.84-1.16)	0.880	1.08 (0.90-1.29)	0.419	1.06 (0.86-1.31)	0.586
T	3	1.21 (1.05-1.39) 0.00	9 1.19 (1.03-1.38)	0.022	1.12 (0.95-1.32)	0.161	1.07 (0.88-1.30)	0.519
T ²	4	2.02 (1.72-2.38) <0.00	01 1.84 (1.54-2.18)	< 0.001	1.42 (1.16-1.73)	< 0.001	1.31 (1.02-1.70)	0.037
N stage N	0	Ref	Ref		Ref			
Ν	1	1.47 (1.35-1.59) <0.00	01 1.51 (1.38-1.66)	< 0.001	1.26 (1.13-1.41)	< 0.001		
N	2	2.30 (2.06-2.56) <0.00	01 2.27 (2.00-2.57)	< 0.001	1.64 (1.40-1.93)	< 0.001		
Chemotherapy N	one/Unknown	Ref	Ref		Ref		Ref	
Y	es	0.65 (0.59-0.71) <0.00	01 0.65 (0.59-0.73)	< 0.001	0.79 (0.70-0.90)	< 0.001	0.83 (0.72-0.96)	0.009

12 HR Hazard ratio

13

14 Table 5. Multivariate analyses of colon-specific deaths in baseline, \geq one-, three-, five-year survivors in the training cohort.

Variables		Baseline survivors		> 1 year survivors		> 3 year survivors		> 5 year survivors	
		HR	р	HR	р	HR	р	HR	р
Age		1.03 (1.02-1.04)	< 0.001	1.04 (1.03-1.05)	< 0.001	1.04 (1.02-1.05)	< 0.001	1.06 (1.03-1.08)	< 0.001
Race	White			Ref		Ref			
	Black			1.26 (1.00-1.60)	0.052	1.32 (0.95-1.84)	0.095		
	Others			0.88 (0.75-1.05)	0.148	0.93 (0.73-1.18)	0.552		
Sex	Male					Ref			
	Female					0.70 (0.59-0.84)	< 0.001		
Year of diagnosis	< 2010	Ref							
	≥2010	0.84 (0.76-0.93)	0.001						
Site	Poximal	Ref				Ref		Ref	
	Distal	1.09 (0.97-1.23)	0.149			1.43 (1.20-1.71)	< 0.001	1.71 (1.34-2.20)	< 0.001
	Others	1.79 (1.26-2.56)	0.001			0.83 (0.37-1.86)	0.649	1.32 (0.42-4.17)	0.632
Grade	Grade I	Ref		Ref					
	Grade II	1.15 (0.90-1.47)	0.266	1.00 (0.77-1.30)	0.981				
	Grade III	1.36 (1.05-1.77)	0.020	0.97 (0.73-1.28)	0.816				
	Grade IV	1.32 (0.94-1.85)	0.109	0.81 (0.54-1.21)	0.300				

Histology type	Adenocarcinoma								
	Mucinous adenocarcinoma	0.96 (0.80-1.15)	0.648						
	Others	0.94 (0.70-1.28)	0.710						
Tumor size	< 5cm	Ref		Ref					
Tumor size	≥5cm	0.96 (0.87-1.07)	0.499	0.90 (0.80-1.02)	0.096				
Marital status	Married	Ref		Ref		Ref			
	Single	1.10 (0.92-1.32)	0.282	1.25 (1.02-1.52)	0.029	1.41 (1.07-1.86)	0.014		
	Widowed	0.99 (0.88-1.11)	0.842	0.98 (0.86-1.13)	0.799	1.15 (0.93-1.41)	0.195		
	Separated/Divorced	1.32 (1.10-1.59)	0.002	1.02 (0.81-1.28)	0.888	1.29 (0.95-1.76)	0.108		
CEA	Negative/Normal	Ref		Ref		Ref		Ref	
	Positive/Elevated	1.55 (1.40-1.72)	< 0.001	1.48 (1.32-1.67)	< 0.001	1.71 (1.45-2.01)	< 0.001	1.41 (1.11-1.81)	0.006
T stage	T1	Ref		Ref		Ref		Ref	
	T2	0.98 (0.69-1.40)	0.903	1.04 (0.70-1.55)	0.844	1.31 (0.78-2.20)	0.299	1.41 (0.75-2.65)	0.281
	Т3	1.98 (1.45-2.70)	< 0.001	2.18 (1.54-3.09)	< 0.001	2.35 (1.49-3.71)	< 0.001	1.88 (1.06-3.32)	0.030
	T4	4.27 (3.09-5.91)	< 0.001	4.34 (3.01-6.26)	< 0.001	3.97 (2.44-6.47)	< 0.001	2.77 (1.45-5.28)	0.002
N stage	N0	Ref		Ref		Ref			
	N1	2.36 (2.08-2.68)	< 0.001	2.60 (2.23-3.02)	< 0.001	1.82 (1.48-2.25)	< 0.001	1.36 (0.99-1.87)	0.056
	N2	4.45 (3.84-5.16)	< 0.001	4.89 (4.11-5.83)	< 0.001	2.94 (2.28-3.79)	< 0.001	1.39 (0.89-2.18)	0.148
Radiation	None/Unknown			Ref					
	Yes			1.52 (0.95-2.43)	0.078				
Chemotherapy	None/Unknown	Ref		Ref		Ref		Ref	
	Yes	0.70 (0.62-0.80)	< 0.001	0.74 (0.63-0.86)	< 0.001	0.94 (0.76-1.17)	0.596	1.12 (0.80-1.58)	0.498

15 HR Hazard ratio









